Your browser doesn't support javascript.
loading
2019 American College of Rheumatology/Arthritis Foundation Guideline for the Screening, Monitoring, and Treatment of Juvenile Idiopathic Arthritis-Associated Uveitis.
Angeles-Han, Sheila T; Ringold, Sarah; Beukelman, Timothy; Lovell, Daniel; Cuello, Carlos A; Becker, Mara L; Colbert, Robert A; Feldman, Brian M; Holland, Gary N; Ferguson, Polly J; Gewanter, Harry; Guzman, Jaime; Horonjeff, Jennifer; Nigrovic, Peter A; Ombrello, Michael J; Passo, Murray H; Stoll, Matthew L; Rabinovich, C Egla; Sen, H Nida; Schneider, Rayfel; Halyabar, Olha; Hays, Kimberly; Shah, Amit Aakash; Sullivan, Nancy; Szymanski, Ann Marie; Turgunbaev, Marat; Turner, Amy; Reston, James.
Afiliação
  • Angeles-Han ST; Cincinnati Children's Hospital Medical Center, University of Cincinnati, Cincinnati, Ohio.
  • Ringold S; Seattle Children's Hospital, Seattle, Washington.
  • Beukelman T; University of Alabama, Birmingham.
  • Lovell D; Cincinnati Children's Hospital Medical Center, University of Cincinnati, Cincinnati, Ohio.
  • Cuello CA; McMaster University, Hamilton, Ontario, Canada.
  • Becker ML; Children's Mercy Hospital, Kansas City, Missouri.
  • Colbert RA; National Institutes of Health, Bethesda, Maryland.
  • Feldman BM; The Hospital for Sick Children, University of Toronto, Toronto, Ontario, Canada.
  • Holland GN; UCLA Stein Eye Institute, David Geffen School of Medicine at UCLA, Los Angeles, California.
  • Ferguson PJ; University of Iowa Carver College of Medicine, Iowa City.
  • Gewanter H; Children's Hospital of Richmond, Virginia Commonwealth University, Richmond.
  • Guzman J; BC Children's Hospital, Vancouver, British Columbia, Canada.
  • Horonjeff J; Columbia University Medical Center, New York, New York.
  • Nigrovic PA; Brigham & Women's Hospital and Boston Children's Hospital, Boston, Massachusetts.
  • Ombrello MJ; National Institutes of Health, Bethesda, Maryland.
  • Passo MH; Medical University of South Carolina, Charleston.
  • Stoll ML; University of Alabama, Birmingham.
  • Rabinovich CE; Duke University, Durham, North Carolina.
  • Sen HN; National Eye Institute, National Institutes of Health, Bethesda, Maryland.
  • Schneider R; The Hospital for Sick Children, University of Toronto, Toronto, Ontario, Canada.
  • Halyabar O; Boston Children's Hospital, Boston, Massachusetts.
  • Hays K; Medical University of South Carolina, Charleston.
  • Shah AA; American College of Rheumatology, Atlanta, Georgia.
  • Sullivan N; ECRI Institute, Plymouth Meeting, Pennsylvania.
  • Szymanski AM; National Institutes of Health, Bethesda, Maryland.
  • Turgunbaev M; American College of Rheumatology, Atlanta, Georgia.
  • Turner A; American College of Rheumatology, Atlanta, Georgia.
  • Reston J; ECRI Institute, Plymouth Meeting, Pennsylvania.
Arthritis Care Res (Hoboken) ; 71(6): 703-716, 2019 06.
Article em En | MEDLINE | ID: mdl-31021540
ABSTRACT

OBJECTIVE:

To develop recommendations for the screening, monitoring, and treatment of uveitis in children with juvenile idiopathic arthritis (JIA).

METHODS:

Pediatric rheumatologists, ophthalmologists with expertise in uveitis, patient representatives, and methodologists generated key clinical questions to be addressed by this guideline. This was followed by a systematic literature review and rating of the available evidence according to the GRADE (Grading of Recommendations Assessment, Development and Evaluation) methodology. A group consensus process was used to compose the final recommendations and grade their strength as conditional or strong.

RESULTS:

Due to a lack of literature with good quality of evidence, recommendations were formulated on the basis of available evidence and a consensus expert opinion. Regular ophthalmic screening of children with JIA is recommended because of the risk of uveitis, and the frequency of screening should be based on individual risk factors. Regular ophthalmic monitoring of children with uveitis is recommended, and intervals should be based on ocular examination findings and treatment regimen. Ophthalmic monitoring recommendations were strong primarily because of concerns of vision-threatening complications of uveitis with infrequent monitoring. Topical glucocorticoids should be used as initial treatment to achieve control of inflammation. Methotrexate and the monoclonal antibody tumor necrosis factor inhibitors adalimumab and infliximab are recommended when systemic treatment is needed for the management of uveitis. The timely addition of nonbiologic and biologic drugs is recommended to maintain uveitis control in children who are at continued risk of vision loss.

CONCLUSION:

This guideline provides direction for clinicians and patients/parents making decisions on the screening, monitoring, and management of children with JIA and uveitis, using GRADE methodology and informed by a consensus process with input from rheumatology and ophthalmology experts, current literature, and patient/parent preferences and values.
Assuntos

Texto completo: 1 Base de dados: MEDLINE Assunto principal: Oftalmologia / Artrite Juvenil / Reumatologia / Uveíte / Produtos Biológicos / Inibidores do Fator de Necrose Tumoral / Glucocorticoides / Imunossupressores Tipo de estudo: Diagnostic_studies / Etiology_studies / Guideline / Prognostic_studies / Risk_factors_studies / Screening_studies / Systematic_reviews Limite: Humans Idioma: En Ano de publicação: 2019 Tipo de documento: Article

Texto completo: 1 Base de dados: MEDLINE Assunto principal: Oftalmologia / Artrite Juvenil / Reumatologia / Uveíte / Produtos Biológicos / Inibidores do Fator de Necrose Tumoral / Glucocorticoides / Imunossupressores Tipo de estudo: Diagnostic_studies / Etiology_studies / Guideline / Prognostic_studies / Risk_factors_studies / Screening_studies / Systematic_reviews Limite: Humans Idioma: En Ano de publicação: 2019 Tipo de documento: Article